CliffBio
small molecule

EDURANT PED

RILPIVIRINE HYDROCHLORIDE

Loss of exclusivityOctober 2037latest FDA-listed patent expiry
CompanyJANSSEN PRODUCTS LP

Drug detail

Brand nameEDURANT PED
Active ingredientRILPIVIRINE HYDROCHLORIDE
StrengthEQ 2.5MG BASE
Dosage formTABLET, FOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2024
Marketing statusRX

Listed patents

PatentExpiresType
11065198October 2037product

Regulatory exclusivity

CodeExpires
PEDSeptember 2027
NPMarch 2027

More from JANSSEN PRODUCTS LP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EDURANT PED patent cliff — loss of exclusivity October 2037 | CliffBio